Research Use Only Disclaimer
This blend is sold strictly for laboratory, academic and institutional research. It is not for human or animal consumption, injection, or any therapeutic, diagnostic or veterinary use. PCH Peptides does not provide dosage, administration or usage guidance.
What Is the CJC-1295 No DAC / Ipamorelin Blend?
The CJC-1295 No DAC / Ipamorelin Blend combines two synthetic research peptides associated with different receptor pathways in the growth hormone axis.
CJC-1295 No DAC, also known as Modified GRF (1-29), is a GHRH analogue studied for its interaction with the growth-hormone-releasing hormone receptor. Ipamorelin is a synthetic pentapeptide investigated for its interaction with the ghrelin receptor (GHS-R1a).
Because the compounds interact with separate receptors, researchers examine them together in dual-receptor signalling models and comparative laboratory studies.
The premixed formulation provides a fixed 1:1 ratio by weight, reducing the need for separate weighing of the two research materials during laboratory preparation.
For more background on these compounds and their research classifications, explore the list of research peptides.
CJC-1295 No DAC / Ipamorelin Blend 20mg Specifications
| Property | Value |
| Components | CJC-1295 No DAC 10mg + Ipamorelin 10mg |
| Total per vial | 20mg |
| Ratio | 1:1 by weight |
| CJC-1295 No DAC molecular weight | 3367.9 g/mol |
| Ipamorelin molecular weight | 711.9 g/mol |
| Form | Lyophilized powder |
| Purity | [Add verified percentage from batch COA] |
Certificate of Analysis
Each blend batch is tested to verify component identity and analytical purity before release. Batch-specific testing documentation helps laboratories assess the quality and consistency of research materials.
The current blend Certificate of Analysis should be reviewed for its verified HPLC purity results and analytical findings. Once available, the applicable COA can be displayed in the product images for convenient reference.
Researchers can review available testing records through the PCH Peptides COA Library, including documentation for the individual peptide compounds.
For additional information about laboratory testing standards and research material documentation, read the guide to Research Use Only Peptides.
Storage and Handling
Keep the vial sealed until it is needed in an authorized laboratory workflow. Store it cold, dry and protected from direct light, following the temperature and handling instructions provided on the product label.
Proper storage helps maintain the stability and integrity of lyophilized research materials during laboratory handling.
Reconstitution Solution is available separately for appropriate laboratory applications.
Researchers seeking general information about lyophilized peptide preparation can review the educational guide on how peptide reconstitution works.
Related Research Materials
Laboratories investigating GHRH-receptor and ghrelin-receptor signalling may examine CJC-1295 No DAC and Ipamorelin individually or as a combined formulation.
For studies requiring independent control over each compound, both peptides are available separately.
- CJC-1295 No DAC – A modified GHRH analogue investigated in receptor-binding, peptide stability and growth hormone-related signalling models.
- Ipamorelin – A synthetic pentapeptide studied for ghrelin-receptor interaction and related molecular signalling pathways.
- Tesamorelin – A stabilized synthetic GHRH analogue used in laboratory research involving receptor interaction and signalling models.
Explore additional compounds through the PCH Peptides research peptide catalog.
Frequently Asked Questions
What is in the CJC-1295 No DAC / Ipamorelin Blend?
Each vial contains 10mg of CJC-1295 No DAC and 10mg of Ipamorelin, providing a total of 20mg of research material in one lyophilized powder formulation.
Why are CJC-1295 and Ipamorelin studied together?
CJC-1295 No DAC and Ipamorelin interact with different receptors. CJC-1295 No DAC targets the GHRH receptor, while Ipamorelin interacts with the ghrelin receptor (GHS-R1a).
Researchers investigate these compounds together in controlled laboratory models to study receptor interactions and signalling pathways associated with the growth hormone axis.
What is the ratio of CJC-1295 No DAC to Ipamorelin in this blend?
The formulation contains a fixed 1:1 ratio by weight, with 10mg of each peptide in a single 20mg vial.
This fixed composition allows laboratories to work with a predefined mixture for comparative research.
Can I buy CJC-1295 No DAC and Ipamorelin separately?
Yes. Both compounds are available as individual research materials.
Researchers can access CJC-1295 No DAC and Ipamorelin separately for studies requiring independent control of each compound.
Is the CJC-1295 No DAC / Ipamorelin Blend tested?
PCH Peptides states that its research peptides undergo batch-specific identity and purity testing. Researchers should review the applicable blend Certificate of Analysis to verify the testing results for the supplied batch.
Available documentation can be accessed through the COA Library.
How should the CJC-1295 No DAC / Ipamorelin Blend be stored?
The blend should be kept sealed, protected from moisture and direct light, and stored according to the temperature recommendations printed on the product label.
Researchers should follow any additional batch-specific storage and handling documentation.
Is the CJC-1295 No DAC / Ipamorelin Blend intended for human use?
No. This blend is supplied exclusively for laboratory, academic and institutional research. It is not intended for human or animal consumption, injection, therapeutic applications or veterinary use.
Additional information about research material classifications is available in the Research Use Only Peptides Guide.
Do you provide dosage instructions for this blend?
No. PCH Peptides does not provide dosage, administration or usage protocols. The CJC-1295 No DAC / Ipamorelin Blend is supplied strictly for qualified research use only.





